MedPage Today January 3, 2026
Research unveiled more possible safety signals and benefits
In January 2025, we reported about an observational study of nearly 2 million U.S. military veterans that showed a broad spectrum of possible risks and benefits associated with GLP-1 receptor agonists. In this report, we follow up on what’s happened since.
In 2025, the American Medical Association proposed a dedicated registry to track adverse events associated with blockbuster diabetes and weight-loss drugs like semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound). The registry has yet to materialize, but the proposal intensified debates about the safety of GLP-1 receptor agonists, including reports of a potentially blinding condition.
Emerging Safety Signals
Semaglutide made headlines in 2025 when the European Medicines Agency warned it may cause...
Today's Sponsors
Today's Sponsor